Table 1.
Baseline characteristics of adalimumab-treated patients and adalimumab exposure by therapeutic indication
| Characteristics | Rheumatoid arthritis | Juvenile idiopathic arthritis | Ankylosing spondylitis | Psoriatic arthritis* | Psoriasis | Crohn's disease | All patients |
|---|---|---|---|---|---|---|---|
| N | 14 109 | 212 | 1684 | 837 | 3010 | 3606 | 23 458 |
| Mean age, years | 53.5 | 11.2 | 43.1 | 48.4 | 44.7 | 37.4 | 48.6 |
| Mean disease duration, years | 9.8† | 3.9† | 10.9 | 14.6† | 19.3 | 11.1† | 11.4† |
| Female, % | 78.9 | 80.2 | 27.5 | 47.4 | 33.2 | 59.7 | 65.3 |
| Receiving concomitant immunosuppressant agents, % | 65.9 | 64.6 | 38.2 | 69.3 | 2.8 | 43.2 | 52.5 |
| Receiving concomitant systemic steroids, % | 64.4 | 53.3 | 35.5 | 26.8 | 4.9 | 34.6 | 48.7 |
| From US sites, % | 23.1 | 47.6 | 8.6 | 25.3 | 37.5 | 37.6 | 26.4 |
| Exposure, PYs | 23 942.6 | 604.9 | 1985.6 | 997.5 | 5061.8 | 4138.0 | 36 730.5 |
| Median duration of exposure, years | 0.7 | 2.6 | 0.4 | 0.4 | 0.7 | 0.5 | 0.6 |
| Maximum duration of exposure, years | 11.8 | 6.9 | 5.1 | 3.5 | 5.7 | 5.5 | 11.8 |
| >2 Years of exposure, N (%) | 2503 (17.7) | 109 (51.4) | 354 (21.0) | 312 (37.3) | 1228 (40.8) | 703 (19.5) | 5209 (22.2) |
| >5 Years of exposure, N (%) | 1646 (11.7) | 64 (30.2) | 140 (8.3) | 0 | 86 (2.9) | 35 (1.0) | 1971 (8.4) |
*
Psoriatic arthritis was the only indication with no new data from those previously reported.10
†
Based on the following number of patients with available baseline disease duration information: rheumatoid arthritis, 13 739; juvenile idiopathic arthritis, 195; psoriatic arthritis, 819; Crohn's disease, 3238; and all patients, 22 685.
PYs, patient-years.